ClinicalTrials.gg
RecruitingNCT07236125Updated May 8, 2026

Dietary Nitrate and the Oral Microbiome in Children With Primary Hypertension

An observational study in Primary Hypertension, sponsored by Yelda Kasımoğlu. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Yelda Kasımoğlu · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
48
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Essential Hypertension with a site in Turkey — 6 open to participants now, 6 under way, none of them phase 3. Essential Hypertension · Turkey.

Started
2026
with 1 other
Observational
2 of 21
1 open now
Registered
17th of 21
by date

Among the 21 studies in Essential Hypertension with a site in Turkey, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 17th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

6 of the 21 studies in Essential Hypertension with a site in Turkey are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Essential Hypertension with a site in Turkey, or all of them as a file.
02

Study summary

Children and adolescents with primary hypertension (high blood pressure without an underlying secondary cause) are at increased risk of cardiovascular disease in adulthood. Recent research suggests that not only the heart and blood vessels, but also the bacteria living in the mouth may play a role in blood pressure regulation. Certain oral bacteria can convert nitrate from food into nitrite and then into nitric oxide, a substance that helps blood vessels relax. If this nitrate-nitrite-nitric oxide pathway is impaired, blood pressure may rise.

This study aims to investigate the relationship between oral microbiota, salivary nitric oxide reductase activity and blood pressure in children and adolescents with primary hypertension compared with healthy peers. We will recruit participants aged 10-18 years who have a diagnosis of primary hypertension and an age- and sex-matched control group without hypertension.

All participants will undergo a non-invasive oral and dental examination and standardized blood pressure measurements. Saliva samples will be collected to measure pH, flow rate, nitrate and nitrite levels, total protein, lysozyme activity and to analyze the composition of oral bacteria using modern DNA-based techniques. Participants and/or their parents will also complete brief questionnaires about diet and general health.

No medication or dietary supplement will be given as part of the study, and no additional blood samples will be taken beyond routine clinical care. The main risk is minimal discomfort related to oral examination and saliva collection. There is no guaranteed direct benefit for participants; however, the results may help us better understand how oral bacteria and salivary nitric oxide pathways are linked to high blood pressure in young people. This knowledge may support the development of new non-invasive strategies for early detection and prevention of hypertension in the future.

Read the detailed description

Primary hypertension (PH) in children and adolescents is increasingly recognized as a significant public health concern. Epidemiological data from multiple cohorts, including the Young Finns Study and other long-term follow-ups, demonstrate that elevated systolic blood pressure beginning in adolescence predicts endothelial dysfunction, increased carotid intima-media thickness, and a higher lifetime risk of cardiovascular morbidity. Children with PH frequently show early subclinical changes such as impaired flow-mediated dilation, increased arterial stiffness, heightened sympathetic activity, and altered nitric oxide (NO) bioavailability. Despite these findings, the early biological mechanisms that contribute to PH in youth remain insufficiently characterized, and non-invasive biomarkers for early detection are limited.

Recent advances in pediatric cardiovascular science suggest that the nitrate-nitrite-nitric oxide (NO₃- → NO₂- → NO) enterosalivary pathway may play a previously underappreciated role in blood pressure regulation. This pathway relies heavily on commensal oral bacteria capable of reducing dietary nitrate to nitrite, which is then swallowed and converted to NO systemically. Any disruption in this oral microbial nitrate-reducing capacity, whether due to dysbiosis, impaired oral hygiene, inflammation, dietary differences, or ecological shifts during adolescence may diminish NO bioavailability and subsequently raise blood pressure. Several adult studies have shown that antibacterial mouthwashes, changes in oral microbiota composition, and reduced salivary nitrate-reducing activity lead to measurable increases in systolic and diastolic blood pressure. However, pediatric data remain extremely scarce, with no comprehensive metagenomic investigation of oral microbiota in children with PH published to date.

This study is therefore designed to characterise, in detail, the relationships between (i) salivary microbiota composition, (ii) nitrate/nitrite conversion capacity, (iii) salivary biochemical characteristics, and (iv) blood pressure profiles in adolescents aged 12-18 years diagnosed with primary hypertension. Importantly, the project employs non-invasive sampling methods (stimulated and unstimulated saliva), enabling participation from children who may not tolerate venipuncture or invasive sampling procedures, and providing a practical model for future screening tools.

  1. Scientific Rationale and Background 1.1. Pediatric Hypertension

    Primary hypertension in youth was once considered rare but now affects up to 3-5% of adolescents globally. It is strongly associated with obesity, insulin resistance, sympathetic overactivation, endothelial dysfunction, and chronic inflammatory states. Although pharmacological treatment is increasingly used, current pediatric guidelines emphasise early identification and non-pharmacological management strategies.

    1.2. Oral Microbiota and Blood Pressure

    The oral cavity hosts over 700 bacterial species, many of which participate in nitrate metabolism. Key nitrate-reducing genera include Veillonella, Neisseria, Rothia, Actinomyces, and Prevotella. Disturbances in these communities due to diet, oral hygiene, frequent mouthwash use, periodontal inflammation, or underlying systemic disease may reduce the efficiency of nitrate reduction.

    Several human trials in adults have demonstrated that:

    mouthwash-mediated suppression of nitrate-reducing bacteria acutely increases blood pressure,

    dietary nitrate supplementation raises salivary nitrite levels and lowers systolic BP,

    individuals with lower nitrate-reducing capacity have higher resting BP.

    However, children fundamentally differ from adults in oral ecology, immune maturation, hormonal shifts during puberty, diet, and salivary gland physiology. Therefore, adult data cannot be extrapolated to pediatric populations.

    1.3. Nitric Oxide, Vascular Function, and Pediatric Risk

    NO is vital for vascular homeostasis. Reduced NO availability contributes to endothelial dysfunction, impaired vasodilation, increased vascular tone, and early arterial stiffness. Several pediatric studies have demonstrated:

    elevated basal NO metabolites in obese children due to chronic low-grade inflammation,

    disrupted NO pathways in children with early metabolic abnormalities,

    correlations between salivary nitrite levels and systemic metabolic markers.

    Yet, no study has simultaneously examined oral microbiome composition + nitrate reductase activity + pediatric hypertension in a unified framework.

  2. Study Objectives and Hypotheses Primary Objective

    To determine whether adolescents with primary hypertension exhibit alterations in oral microbiota composition and reduced salivary nitrate-reducing capacity compared with normotensive controls.

    Secondary Objectives

    To quantify salivary nitrate, nitrite, pH, flow rate, total protein, lysozyme activity and correlate these with blood pressure levels.

    To explore associations between oral microbial diversity (alpha/beta diversity metrics) and hypertension status.

    To identify specific bacterial taxa or functional gene pathways (via metagenomic sequencing) associated with impaired nitrate reduction.

    To evaluate whether salivary microbiome features could serve as non-invasive biomarkers for early vascular risk or masked hypertension.

    To explore relationships between nitrate-related pathways and anthropometric measures, oral health indices, diet, and lifestyle.

    Hypotheses

    Children with PH have distinct oral microbial compositions with lower abundance of nitrate-reducing bacteria.

    Reduced nitrate-reducing capacity is associated with lower salivary nitrite, altered NO metabolism, and higher systolic BP.

    Specific microbial signatures may predict masked hypertension and early vascular dysfunction.

  3. Study Design

    This is a observational, cross-sectional, non-interventional clinical study. No therapeutic agents or dietary supplements will be administered. All measurements rely on non-invasive, routine pediatric dental and clinical procedures.

    3.1. Participants

    Two groups will be recruited:

    Primary Hypertension Group (PH Group)

    Diagnosed according to AAP and ESH pediatric hypertension criteria.

    Healthy Control Group

    Age- and sex-matched.

    Normotensive based on standardized clinic measurements.

    3.2. Sample size

    Based on prior microbiome variability estimates and effect sizes in adult nitrate-reduction studies, a minimum of 48 participants is planned (24 PH + 24 control). This number is adequate for exploratory metagenomic and metabolite correlations. Power calculations used α=0.05 and β=0.20 for differences in nitrate reduction capacity.

  4. Data Collection Procedures 4.1. Blood Pressure Measurement

    Performed using pediatric cuff-adjusted oscillometric devices validated for clinical use.

    Measurements taken after 5 minutes of rest, in a seated position, using three repeated readings.

    4.2. Clinical Oral Examination

    Conducted by a trained pediatric dentist.

    Assessment includes dental caries, gingival status, and plaque presence.

    4.3. Saliva Collection (Unstimulated)

    Unstimulated saliva for baseline nitrate/nitrite measurements, pH, flow rate, total protein.

    Standardized collection times (morning hours, ≥1 hr after eating, drinking, brushing).

    4.4. Laboratory Measurements

    Biochemical analyses

    Nitrate and nitrite concentrations via standardized kits (colorimetric methods).

    Salivary lysozyme activity (innate immunity marker).

    Total protein via BCA assay.

    pH via pH strips.

    Metagenomic DNA Extraction

    Using a microbiome DNA extraction kit ensuring lysis of both Gram-positive and Gram-negative bacteria.

    Library Preparation for NGS

    Metagenomics library preparation kit

    DNA barcoding kit

    Library quantification and normalization using Illumina-based quantification kits.

    Sequencing

    Performed using Illumina MiSeq 2×300 bp paired-end sequencing.

    Quality control steps include fragment size profiles, chimera removal, and adapter trimming.

    Bioinformatics Pipeline

    FASTQ quality filtering using QIIME2 or similar platforms.

    Taxonomic classification using SILVA/Greengenes/HOMD reference databases.

    Functional analysis via PICRUSt2 or equivalent tools.

    Diversity analyses with Shannon, Simpson, Bray-Curtis metrics.

  5. Data Management and Quality Assurance 5.1. Data Validation

    All collected data will undergo range checks and logical consistency checks (e.g., BP ranges, anthropometric plausibility).

    Automated scripts will flag inconsistencies for review.

    5.2. Source Verification

    Clinical data will be reviewed against patient charts by trained clinicians.

    Saliva processing forms will be cross-checked with laboratory data.

    5.3. Laboratory QC

    Use of negative/blank controls during DNA extraction and library preparation.

    Duplicate samples for \~10% of participants to assess technical variability.

    Calibration logs for pipettes, thermocyclers, and sequencing equipment.

    5.4. Data Security

    Data stored on institutional encrypted servers behind firewall protection.

    Only authorized team members will have access.

  6. Statistical Analysis Plan 6.1. Primary Analysis

    Compare microbial diversity and nitrate-reducing capacity between PH and control groups using:

    Wilcoxon/Mann-Whitney U tests

    PERMANOVA for beta-diversity

    Differential abundance analysis (ANCOM, DESeq2)

    6.2. Secondary Analyses

    Spearman correlations between salivary biochemical markers and systolic/diastolic BP.

    Multiple linear regression adjusting for BMI, diet, oral hygiene habits.

    Exploratory machine-learning models (random forest) to identify predictive microbial features.

    6.3. Missing Data Plan

    Missing biochemical values handled via multiple imputation or complete case analysis.

    Missing microbiome data due to low DNA yield will be documented, not imputed.

  7. Ethical Considerations

    This study involves minimal risk. No blood samples, medications, or interventions will be given. Saliva collection is non-invasive and well tolerated. Consent and assent procedures will be conducted according to institutional and national regulations.

    Ethical approval was obtained from the Istanbul University Faculty of Dentistry Clinical Research Ethics Committee at its meeting dated 14/10/2025 and numbered 206.

  8. Potential Impact

The project may reveal novel, non-invasive microbial signatures of early vascular risk in adolescents. Findings could support:

early screening tools for masked or mild hypertension,

dietary nitrate-based preventive strategies,

better understanding of the oral microbiome-vascular axis in youth.

03

Conditions studied

  • Primary Hypertension

Keywords

  • primary hypertension
  • oral microbiome
  • nitrate-reduction bacteria
  • salivary nitrite
  • salivary nitrate
  • pediatric hypertension
  • Enterosalivary Nitrate Cycle
  • Adolescent Hypertension
  • Salivary Microbiome
  • Nitrate-Nitrite-Nitric Oxide Pathway
  • Saliva Biomarkers
  • Endothelial Dysfunction
  • Blood Pressure in Adolescents
  • Non-invasive Biomarkers
  • Saliva-Based Diagnostics
04

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from children and adolescents aged 10-18 years presenting to the Istanbul University Faculty of Dentistry, Department of Pediatric Dentistry, as well as pediatric patients followed by the Pediatric Nephrology Clinic who have been diagnosed with primary hypertension. The study population includes two groups: (1) adolescents with confirmed primary hypertension, not on antihypertensive medication, and (2) age- and sex-matched healthy controls without systemic disease or blood pressure abnormalities. All participants will be systemically healthy, cooperative, and able to provide saliva samples, undergo oral examinations, and complete questionnaire assessments. Recruitment will be consecutive based on clinic attendance, and all participants and their families will be informed about study procedures before enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Applied to the Istanbul University Faculty of Medicine, Department of Pediatric Nephrology,
  • Between the ages of 10 and 18,
  • Diagnosed with primary hypertension,
  • Clinically excluded from secondary hypertension or heart failure,
  • No systemic or chronic disease other than hypertension,
  • No periodontal disease, dental infection, or oral mucosal disease,
  • Not taking regular antihypertensive or other medications for a chronic disease,
  • Not having received antibiotic treatment in the last 3 months,
  • Patients who have not used mouthwash in the last 3 months,
  • Have no allergies to nitrate-rich foods,
  • Both male and female patients will be included.

Exclusion criteria

Exclusion Criteria:

  • Younger than 10 years of age or older than 18 years of age
  • Clinically diagnosed with secondary hypertension or heart failure
  • Have a systemic disease
  • Have periodontal disease, dental infection, or oral mucosal disease
  • Are taking regular antihypertensive medications or other chronic illnesses
  • Have received antibiotic treatment within the last 3 months
  • Have used mouthwash within the last 3 months
  • Are allergic to nitrate-rich foods will not be included in the study.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
48 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with primary hypertension

    This group includes adolescents aged 10-18 years who have been clinically diagnosed with primary hypertension based on repeated office blood pressure measurements according to pediatric hypertension guidelines. Participants will undergo standardized assessments including oral examination, blood pressure measurements, salivary collection, and laboratory analyses. Laboratory procedures include: oral microbiota profiling through 16S rRNA gene sequencing, quantification of nitrate-reducing bacterial activity, measurement of salivary pH, total protein concentration, and lysozyme activity. No therapeutic intervention will be administered. All procedures are observational and aim to characterize microbial and biochemical markers associated with primary hypertension.

    Other: No active intervention

  • Healthy controls

    This group includes healthy adolescents aged 10-18 years with no history of primary or secondary hypertension, chronic systemic disease, or regular medication use affecting cardiovascular or oral microbiome physiology. Participants will undergo standard clinical assessments identical to the hypertension group, including oral examination, salivary collection, and blood pressure measurement. Laboratory procedures will include salivary microbiota analysis (16S rRNA sequencing), assessment of nitrate-reducing bacterial activity, salivary pH, total protein concentration, and lysozyme activity. This cohort serves as the normative comparison group to evaluate microbial and biochemical differences associated with primary hypertension. No intervention will be administered.

    Other: No active intervention

Interventions

  • OtherNo active intervention

    This is an observational study with no active intervention. No drug, device, behavioral, dietary, surgical, or diagnostic intervention is administered to participants. All study procedures, including oral examination, salivary sampling, pH measurement, biochemical tests, and blood pressure assessment, are non-interventional and part of standard clinical evaluation. The study only aims to observe natural variations in oral microbiota composition, nitrate-reducing activity, and blood pressure without changing participants' medical care.

06

What researchers measure

Primary outcomes

  1. Microbiota Composition (16S rRNA Sequencing)

    Characterization of bacterial community diversity and relative abundance in unstimulated saliva using 16S rRNA gene sequencing. Analysis will include alpha diversity, beta diversity, and differential taxa abundance between groups, with a focus on nitrate-reducing genera such as Neisseria, Rothia, and Actinomyces.

    Time frame: Baseline

Secondary outcomes

  1. Salivary Nitrate and Nitrite Levels

    Quantitative measurement of salivary nitrate-to-nitrite conversion capacity using colorimetric assays. The activity of nitrate-reducing oral bacteria will be assessed by determining nitrite concentrations produced in vitro from standardized nitrate substrate under controlled incubation. Higher nitrite output indicates higher nitrate-reductase activity. Values will be compared between primary hypertension patients and healthy controls.

    Time frame: Baseline (single visit)

  2. Salivary pH

    Salivary acidity/alkalinity measured using validated pH indicator strips immediately after sample collection. Values will be compared between hypertensive and healthy groups.

    Time frame: Baseline

  3. Salivary Flow Rate

    Unstimulated salivary flow rate (mL/min) collected over a timed period (5 minutes). Reduced flow may influence oral microbiota composition and nitrate metabolism.

    Time frame: baseline

  4. Salivary Lysozyme Activity

    Quantitative assessment of innate immune enzyme lysozyme using a commercial colorimetric assay. Alterations in antimicrobial enzyme levels may influence microbial ecology.

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Li D, Nishi SK, Jovanovski E, Zurbau A, Komishon A, Mejia SB, Khan TA, Sievenpiper JL, Milicic D, Jenkins A, Vuksan V. Repeated administration of inorganic nitrate on blood pressure and arterial stiffness: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2020 Nov;38(11):2122-2140. doi: 10.1097/HJH.0000000000002524. PubMed 32723980 ↗
  • Broxterman RM, La Salle DT, Zhao J, Reese VR, Richardson RS, Trinity JD. Influence of dietary inorganic nitrate on blood pressure and vascular function in hypertension: prospective implications for adjunctive treatment. J Appl Physiol (1985). 2019 Oct 1;127(4):1085-1094. doi: 10.1152/japplphysiol.00371.2019. Epub 2019 Aug 15. PubMed 31414959 ↗
  • Carey RM, Wright JT Jr, Taler SJ, Whelton PK. Guideline-Driven Management of Hypertension: An Evidence-Based Update. Circ Res. 2021 Apr 2;128(7):827-846. doi: 10.1161/CIRCRESAHA.121.318083. Epub 2021 Apr 1. PubMed 33793326 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2025
First posted
Nov 19, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Sep 15, 2026
CompletionEst.
Jan 15, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07236125
Lead sponsor
Yelda Kasımoğlu
Collaborators
Istanbul University Scientific Research Projects Coordination Unit- Pending
Responsible party
Yelda Kasımoğlu (Assoc. Prof., Istanbul University) — Sponsor-investigator
First posted
Nov 19, 2025
Start date
Apr 15, 2026
Primary completion
Sep 15, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Yelda Kasimoglu Assoc. Prof.
Contact
yelda.kasimoglu@iu.edu.tr
+90 533 623 39 78

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion